维罗纳制药
VRNA

From March 31, 2025 to June 30, 2025 Restricted share units vested Share options exercised

From December 31, 2024 to March 31, 2025 Restricted share units vested Share options exercised

From December 31, 2023 to December 31, 2024 Share options exercised Issuance of common shares under at-the-market sales agreement Restricted share units vested Issuance of ordinary shares to treasury

From June 30, 2024 to September 30, 2024 Restricted share units vested Share options exercised

From December 31, 2023 to March 31, 2024 Restricted share units vested Share options exercised

From December 31, 2022 to December 31, 2023 Issuance of common shares under at-the-market sales agreement Issuance of ordinary shares to treasury

From June 30, 2023 to September 30, 2023 Restricted share units vested Share options exercised

From March 31, 2023 to June 30, 2023 Restricted share units vested Share options exercised

From December 31, 2022 to March 31, 2023 Issuance of ordinary shares Share options exercised Restricted share units vested

From December 31, 2021 to December 31, 2022 Issuance of ordinary shares, net of issuance costs Share options exercised Issuance of common shares under at-the-market sales agreement Restricted share units vested Issuance of ordinary shares to treasury

From June 30, 2022 to September 30, 2022 Issuance of ordinary shares, net of issuance costs Restricted share units vested

1.ADSs offered by 12,400,000 ADSs 2.The number of ordinary shares (including ordinary shares represented by ADSs) to be outstanding immediately after this offering is based on 487,633,374 ordinary shares outstanding as of August 1, 2022

From March 31, 2022 to June 30, 2022 Restricted share units vested

From June 30, 2021 to September 30, 2021 Issuance of common shares under at-the-market sales agreement Restricted share units vested

From March 31, 2021 to June 30, 2021 Issuance of common shares under at-the-market sales agreement Restricted share units vested

From December 31, 2019 to December 31, 2020 Issuance of ordinary shares, net of issuance costs Issuance of ordinary shares to treasury Issuance of ordinary shares from restricted share units and share options

On July 17, 2020, Verona Pharma plc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”). Pursuant to the Purchase Agreement, the Company agreed to sell an aggregate of 38,440,009 of its American Depositary Shares (the “ADSs”), each representing eight Ordinary Shares of the Company, nominal value ￡0.05 per share (the “Ordinary Shares”) and 48,088,896 Non-Voting Ordinary Shares of the Company, nominal value ￡0.05 per share (the “Non-Voting Ordinary Shares”), to the Investors, at a purchase price equal to $4.50 per ADS and $0.5625 per Non-Voting Ordinary Share (the “Private Placement”). The Company also agreed to sell 222,216 Ordinary Shares to a director at a purchase price per share of ￡0.45 (the “Subscription”). The Purchase Agreement contained customary representations and warranties from the Company and the Investors and customary closing conditions. The closing of the Private Placement and the Subscription occurred on July 22, 2020 (the “Closing Date”).

from January 1, 2018 to December 31, 2018 New share capital issued

from January 1, 2017 to December 31, 2017 New share capital issued Share options exercised during the period

Global offering 47,399,001 ordinary shares offered by us, consisting of ordinary shares in the form of ADSs offered in the U.S. offering and ordinary shares offered in the European private placement. The closing of each of the U.S. offering and the European private placement is conditioned upon the other. U.S. offering 5,768,000 ADSs, each ADS representing eight ordinary shares. European private placement 1,255,001 ordinary shares